2021 hospital crisis in the U.S. from COVID-19

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

Retrieved on: 
Saturday, March 11, 2023
Mental Health, Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Vanderbilt University Medical Center, Kidney, Plasma, MECP2, Syndrome, Patient, Multimedia, Division, 2021 hospital crisis in the U.S. from COVID-19, Webcast, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Diarrhea, ASX, OATP1B1, Neurodevelopmental disorder, Caregiver, Clinical Global Impression, ACAD, PIN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CYP3A4, Food, Toxic encephalopathy, Weight loss, Vomiting, Recurrence, OATP1B3, Laxative, Rett syndrome, Safety, Dehydration, Female, Special education, Gait, Communication, Pharmaceutical industry, Nursing, Rett, Pediatrics, Pharmacology

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.
  • DAYBUE is the first and only drug approved for the treatment of Rett syndrome.
  • View the full release here: https://www.businesswire.com/news/home/20230303005382/en/
    "Today marks an important milestone for the Rett community and Acadia.
  • Acadia management will discuss the FDA approval of DAYBUE for the treatment of Rett syndrome via conference call and webcast on Monday, March 13, 2023 at 8:30 a.m. Eastern Time.